Cargando…
Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients
BACKGROUND: Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection. METHODS: We se...
Autores principales: | Han, Liping, Jiang, Qiufang, Yao, Wei, Fu, Tian, Zeng, Qingdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035446/ https://www.ncbi.nlm.nih.gov/pubmed/29980186 http://dx.doi.org/10.1186/s12885-018-4581-5 |
Ejemplares similares
-
Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer
por: Fu, Tian, et al.
Publicado: (2020) -
Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions
por: Biaoxue, Rong, et al.
Publicado: (2015) -
Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2020) -
Immune Regulation of Interleukin-27 in Malignant Pleural Effusion
por: Li, Shi, et al.
Publicado: (2015) -
Diagnostic role of interleukin -33 in the differentiation of pleural effusions especially tuberculous and malignant effusions
por: Al-aarag, Abdel-sadek Hamed, et al.
Publicado: (2019)